Qual é o preço para Bristol-Myers Squibb Company (BMY)

O preço para Bristol-Myers Squibb Company (BMY) é $62.26

Qual é a capitalização de mercado para Bristol-Myers Squibb Company (BMY)

A capitalização de mercado para Bristol-Myers Squibb Company (BMY) é $127.18B

Bristol-Myers Squibb Company (BMY) Rendimento de Dividendos

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Ano	Rendimento de Dividendos	Alterar
2026 (TTM)	3.92%	-14.78%
2025	4.60%	8.49%
2024	4.24%	-5.15%
2023	4.47%	48.01%
2022	3.02%	-4.73%
2021	3.17%	8.93%
2020	2.91%	18.78%
2019	2.45%	-20.45%
2018	3.08%	20.31%
2017	2.56%	-1.92%
2016	2.61%	20.83%
2015	2.16%	-11.84%
2014	2.45%	-7.20%
2013	2.64%	-37.14%
2012	4.20%	11.70%
2011	3.76%	-22.47%
2010	4.85%	-2.61%
2009	4.98%	-6.92%
2008	5.35%	26.18%
2007	4.24%	-0.47%
2006	4.26%	-12.53%
2005	4.87%	11.44%
2004	4.37%	11.48%
2003	3.92%	-16.42%
2002	4.69%	117.13%
2001	2.16%	54.29%
2000	1.40%	0.00%

Ano

Rendimento de Dividendos

Alterar

2026 (TTM)

3.92%

-14.78%

2025

4.60%

8.49%

2024

4.24%

-5.15%

2023

4.47%

48.01%

2022

3.02%

-4.73%

2021

3.17%

8.93%

2020

2.91%

18.78%

2019

2.45%

-20.45%

2018

3.08%

20.31%

2017

2.56%

-1.92%

2016

2.61%

20.83%

2015

2.16%

-11.84%

2014

2.45%

-7.20%

2013

2.64%

-37.14%

2012

4.20%

11.70%

2011

3.76%

-22.47%

2010

4.85%

-2.61%

2009

4.98%

-6.92%

2008

5.35%

26.18%

2007

4.24%

-0.47%

2006

4.26%

-12.53%

2005

4.87%

11.44%

2004

4.37%

11.48%

2003

3.92%

-16.42%

2002

4.69%

117.13%

2001

2.16%

54.29%

2000

1.40%

0.00%

Empresa	Rendimento de Dividendos	País
Eli Lilly and Company LLY.US	0.59%	US
Johnson & Johnson JNJ.US	1.98%	US
AbbVie Inc. ABBV.US	2.61%	US
Roche Holding AG RO.SW	2.69%	CH
Merck & Co., Inc. MRK.US	2.35%	US

Empresa

Rendimento de Dividendos

País